Top Tweets for #1Ad
#1AD ($11M MC) NEWS💥
We might have a #CancerCure for #Mesothelioma patients here folks👇❤️
⏩️TWO ADVANCED #MESOTHELIOMA PATIENTS continue in follow-up in the ongoing China clinical study, INCLUDING THE SECOND COMPLETE RESPONDER, with NEXT FORMAL ASSESSMENTS EXPECTED IN EARLY 2027⏪️
⏩️@AdAlta1AD & #SHCells EW-001 Joint Development Committee approves @FDA briefing pack & manufacturing technology transfer plan⏪️
• the first patient to achieve a complete response, having completed the final study assessment point two years after treatment with no evidence of cancer returning, has completed the study
• two patients were assessed as having progressive disease (their cancer had grown relative to baseline pre-treatment) having previous achieved a partial response and stable disease respectively and, as per protocol, were withdrawn from formal follow-up; and
• two patients remain on study with planned follow-up: the second complete response patient, who, as previously reported, has passed one year of survival and is next due for assessment at 18 months, and a patient whose disease remained stable (tumours not growing) at their six month assessment.
#ASX #BioTech #CarT #CellTherapy #Cancer @CancerCouncilOz @CCNewSouthWales @CancerVic @CancerCouncilSA @CancerCouncilWA
#1AD 👇👇👇
#1AD ($11M MC) NEWS💥
We might have a #CancerCure for #Mesothelioma patients here folks👇❤️
⏩️TWO ADVANCED #MESOTHELIOMA PATIENTS continue in follow-up in the ongoing China clinical study, INCLUDING THE SECOND COMPLETE RESPONDER, with NEXT FORMAL ASSESSMENTS EXPECTED IN EARLY 2027⏪️
⏩️@AdAlta1AD & #SHCells EW-001 Joint Development Committee approves @FDA briefing pack & manufacturing technology transfer plan⏪️
• the first patient to achieve a complete response, having completed the final study assessment point two years after treatment with no evidence of cancer returning, has completed the study
• two patients were assessed as having progressive disease (their cancer had grown relative to baseline pre-treatment) having previous achieved a partial response and stable disease respectively and, as per protocol, were withdrawn from formal follow-up; and
• two patients remain on study with planned follow-up: the second complete response patient, who, as previously reported, has passed one year of survival and is next due for assessment at 18 months, and a patient whose disease remained stable (tumours not growing) at their six month assessment.
#ASX #BioTech #CarT #CellTherapy #Cancer @CancerCouncilOz @CCNewSouthWales @CancerVic @CancerCouncilSA @CancerCouncilWA
#1AD ($11M MC) NEWS💥
We might have a #CancerCure for #Mesothelioma patients here folks👇❤️
⏩️TWO ADVANCED #MESOTHELIOMA PATIENTS continue in follow-up in the ongoing China clinical study, INCLUDING THE SECOND COMPLETE RESPONDER, with NEXT FORMAL ASSESSMENTS EXPECTED IN EARLY 2027⏪️
⏩️@AdAlta1AD & #SHCells EW-001 Joint Development Committee approves @FDA briefing pack & manufacturing technology transfer plan⏪️
• the first patient to achieve a complete response, having completed the final study assessment point two years after treatment with no evidence of cancer returning, has completed the study
• two patients were assessed as having progressive disease (their cancer had grown relative to baseline pre-treatment) having previous achieved a partial response and stable disease respectively and, as per protocol, were withdrawn from formal follow-up; and
• two patients remain on study with planned follow-up: the second complete response patient, who, as previously reported, has passed one year of survival and is next due for assessment at 18 months, and a patient whose disease remained stable (tumours not growing) at their six month assessment.
#ASX #BioTech #CarT #CellTherapy #Cancer @CancerCouncilOz @CCNewSouthWales @CancerVic @CancerCouncilSA @CancerCouncilWA
#1AD ($11M MC) NEWS💥
IMO Most Undervalued #Biotech Play in #ASX
⏩️APPROVAL RECEIVED from SHANGHAI MUNICIPAL ADMINISTRATION FOR MARKET REGULATION to OPEN A REPRESENTATIVE OFFICE in #SHANGHAI 🇨🇳, giving #1AD the ability to engage local staff & contractors to represent & promote @AdAlta1AD in #China⏪️
About #1AD EW-001👇💥
#Cancer #CancerCure #Mesothelioma
⏩️EW-001 is a novel, FIRST IN CLASS, #CarT #CellTherapy designed to treat #Mesothelioma (a rare but rapidly fatal cancer usually linked to asbestos exposure) & with possible application in more than ten other cancers⏪️
EW-001 clinical studies in relapsed or advanced mesothelioma patients (second line and later) in China have reported👇💥
💥UP TO 50% OVERALL RESPONSE RATE (tumour shrinkage)
💥UP TO 20% COMPLETE RESPONSE RATE (complete tumour clearance)
💥Two patients achieving Complete Responses have NOW REACHED TWO & ONE YEAR SURVIVAL MILESTONES respectively with no evidence of cancer returning providing evidence of durability of response
💥Median overall survival has not yet been reached in the current generation manufacturing process, however an EARLIER GENERATION OF EW-001 ACHIEVED MORE THAN 25 MONTHS MEDIAN SURVIVAL
EW-001 update: our Joint Development Committee with SHcell has approved the briefing pack for our FDA pre-IND meeting and how EW-001 will be made in Australia. First Australian manufacturing runs anticipated in 2H 2026.
Join the conversation at: https://t.co/1rCR8wUuOo
#1AD
#1AD #cancer #CART #biotech
EW-001 Joint Development Committee approves FDA briefing
pack and manufacturing technology transfer plan
AdAlta and its partner Shanghai Cell Therapy Group have formally approved
the next two steps on the path to clinical trials of EW-001 in Australia..
Progress happening at a decent pace..
ADALTA LIMITED ( #1AD ) has released " EW-001 JDC milestone approvals " on Mon 05 Oct at 8:24 am AEST #China #ClinicalTrials #Strategy
EW-001 update: our Joint Development Committee with SHcell has approved the briefing pack for our FDA pre-IND meeting and how EW-001 will be made in Australia. First Australian manufacturing runs anticipated in 2H 2026.
Join the conversation at: https://t.co/1rCR8wUuOo
#1AD
Can’t believe it’s been 20 years and a Day brother I remember the last time we talked you had just got home from mid tour. Deeds Spartan till we meet again #36thinfantryregiment #1AD
BIG WEEKEND AHEAD🥃💥
2 nights mates weekend & then Tues night taking the family to Norway 🇳🇴 see the northern lights
Still no sign of market recovery but we will never give up💪💥
HAGW #Fintwit Fam🥂
#ASX #Investing #Stocks
$DAL $CRR $ALR $PKO #1AD $NVU $DVL $PMM $VMM $SIS
HAGW Folks🥂🥃
Red day to finish the week, but we never quit💪😎
Hard to believe last mini #ASX small cap bull run started in Oct 2025 almost 1 year ago, but since then lot of stocks lost more than 60% from the highs...
Hang in there guys, maybe the next bull run is just 1-2 months away😜
$ALR $DAL $PKO $CRR $DVL $NVU #1AD $SIS $PMM #I88
#1AD ($11M MC) NEWS💥
IMO Most Undervalued #Biotech Play in #ASX
⏩️APPROVAL RECEIVED from SHANGHAI MUNICIPAL ADMINISTRATION FOR MARKET REGULATION to OPEN A REPRESENTATIVE OFFICE in #SHANGHAI 🇨🇳, giving #1AD the ability to engage local staff & contractors to represent & promote @AdAlta1AD in #China⏪️
About #1AD EW-001👇💥
#Cancer #CancerCure #Mesothelioma
⏩️EW-001 is a novel, FIRST IN CLASS, #CarT #CellTherapy designed to treat #Mesothelioma (a rare but rapidly fatal cancer usually linked to asbestos exposure) & with possible application in more than ten other cancers⏪️
EW-001 clinical studies in relapsed or advanced mesothelioma patients (second line and later) in China have reported👇💥
💥UP TO 50% OVERALL RESPONSE RATE (tumour shrinkage)
💥UP TO 20% COMPLETE RESPONSE RATE (complete tumour clearance)
💥Two patients achieving Complete Responses have NOW REACHED TWO & ONE YEAR SURVIVAL MILESTONES respectively with no evidence of cancer returning providing evidence of durability of response
💥Median overall survival has not yet been reached in the current generation manufacturing process, however an EARLIER GENERATION OF EW-001 ACHIEVED MORE THAN 25 MONTHS MEDIAN SURVIVAL
#1AD 🔥🔥
#AdAlta has approval to open a representative office in Shanghai.
Local presence on the ground in China to manage the SHcell collaboration, find new partners, and scale the East-to-West cell therapy model. EW-001 is first.
Still Australian domiciled. IP stays outside China.
#1AD 🔥🔥
First FDA meeting on EW-001 is now booked for early November.
@YellowStripeASX #1AD should be a $50mill MC company ATM, at minimum.
Chinese investors can 1st hand finnaly see what we have, and 💰 should flow into #1AD all going well.
#1AD ($11M MC) NEWS💥
IMO Most Undervalued #Biotech Play in #ASX
⏩️APPROVAL RECEIVED from SHANGHAI MUNICIPAL ADMINISTRATION FOR MARKET REGULATION to OPEN A REPRESENTATIVE OFFICE in #SHANGHAI 🇨🇳, giving #1AD the ability to engage local staff & contractors to represent & promote @AdAlta1AD in #China⏪️
About #1AD EW-001👇💥
#Cancer #CancerCure #Mesothelioma
⏩️EW-001 is a novel, FIRST IN CLASS, #CarT #CellTherapy designed to treat #Mesothelioma (a rare but rapidly fatal cancer usually linked to asbestos exposure) & with possible application in more than ten other cancers⏪️
EW-001 clinical studies in relapsed or advanced mesothelioma patients (second line and later) in China have reported👇💥
💥UP TO 50% OVERALL RESPONSE RATE (tumour shrinkage)
💥UP TO 20% COMPLETE RESPONSE RATE (complete tumour clearance)
💥Two patients achieving Complete Responses have NOW REACHED TWO & ONE YEAR SURVIVAL MILESTONES respectively with no evidence of cancer returning providing evidence of durability of response
💥Median overall survival has not yet been reached in the current generation manufacturing process, however an EARLIER GENERATION OF EW-001 ACHIEVED MORE THAN 25 MONTHS MEDIAN SURVIVAL
#1AD $10M MC
💥MAJOR CLINICAL UPDATE💥
⏩Tumour shrinkage, clearance in advanced #mesothelioma patients treated with BZDS1901 support exploration of higher dosing, further clinical development⏪
• All five advanced mesothelioma patients in extension Cohort 1 of the investigator-initiated trial of BZDS1901 have passed at least two months of follow-up
• 14 mesothelioma patients now treated: all had either previously not responded to, or relapsed after, chemotherapy or immunotherapy
• Five of the ten patients receiving the highest doses of BZDS1901 are seeing tumour shrinkage of more than 30% (50% Overall Response Rate)
#1AD
#AdAlta opens a representative office in Shanghai
Approval gives #AdAlta the ability to put its own people on the ground in China, strengthening the engine room of the "East to West" strategy.,
Increases #AdAlta's profile inside the world's most active source of #cellular #immunotherapy #innovation - more than 970 clinical trials and over 350 developers.
#1AD @AdAlta1AD Opens Representative office in Shanghai #China
#1AD Chinese investment about to exploded IMO.
ADALTA LIMITED ( #1AD ) has released " China Representative Office opens " on Thu 01 Oct at 8:42 am AEST #China #ClinicalTrials #Strategy
#1AD
a massive step forward...well done management
💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎
AdAlta opens a representative office in Shanghai. We are on the ground in the world’s most active source of cell therapy innovation, and where our next pipeline candidates will be found.
Check out the full announcement, join the conversation at: https://t.co/FPKqq9IPcx
#1AD
#1AD #cancer #cartTherapy
"AdAlta opens a representative office in Shanghai"
Gets the ability to put its own people on the ground in
China, strengthening the engine room of the “East to West” strategy
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers